Yahoo
Morningstar

Morningstar

•

Nov 02, 2026

Sanofi: Sanofi Earnings: Guidance Upgraded as Pharma Launches and Dupixent Drive Growth

Symbols

SNY

Sector(s)

Healthcare

Rating

Current Price

45.55

Fair Value

Economic Moat

Stewardship

Summary

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level

Upgrade
Mobilize your Website
View Site in Mobile | Classic
Share by: